Dyadic International Inc (DYAI)

[tykundegex]

Glycoengineering of the C1 strain, to make it more "human like".

Here is a description: "While most products to date are produced in mammalian cell cultures, namely Chinese hamster ovary cells, plant-based production systems gained increasing acceptance over the last years. Different plant systems have been established which are suitable for standardization and precise control of cultivation conditions, thus meeting the criteria for pharmaceutical production. The majority of biopharmaceuticals comprise glycoproteins. Therefore, differences in protein glycosylation between humans and plants have to be taken into account and plant-specific glycosylation has to be eliminated to avoid adverse effects on quality, safety, and efficacy of the products. "

Essentially, if they can do this, they are dramatically less likely to produce drugs/vaccines/antibodies that will have side-effects: more tolerable, safer, and more effective.